A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice
A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice
复制标题
DOI：
10.1111/j.1476-5381.2009.00270.x
复制
发表时间：
2009-07-01
影响因子：
7.3
通讯作者：
Galvez, J.
中科院分区：
文献类型：
--
作者：
Arribas, B.;Rodriguez-Cabezas, M. E.;Galvez, J.
背景和目的：大肠杆菌Nissle 1917是一种益生菌菌株，用于治疗肠道免疫疾病，包括溃疡性结肠炎。本研究的目的是测试这种益生菌在口服给药后是否也可以显示出全身免疫调节特性。将益生菌菌株给予大鼠或小鼠2周，然后在两种免疫应答改变的实验模型中进行测定，即大鼠结肠炎的三硝基苯磺酸（TNBS）模型，局限于结肠，和脂多糖（LPS）诱导的小鼠感染性休克模型。在TNBS模型中1周后或在LPS休克模型中24小时后，通过肉眼和生化方法评估炎症状态。此外，从小鼠中获得脾细胞，并用伴刀豆球蛋白A或LPS离体刺激以分别激活T或B细胞，并测量T细胞产生的细胞因子（IL-2、IL-5和IL-10）和B细胞的IgG分泌。关键结果：E. coli Nissle 1917在免疫应答改变的两种模型中均具有抗炎作用。这包括在结肠炎大鼠的肠中以及用LPS处理的小鼠的血浆和肺中的促炎细胞因子肿瘤坏死因子-α的减少。全身有益作用与抑制T细胞细胞因子的产生和下调脾细胞来源的B细胞的IgG释放有关。大肠杆菌Nissle 1917口服给药不限于胃肠道。英国药理学杂志（2009）157，1024-1033; doi：10.1111/j.1476-5381.2009.00270.x; 2009年5月26日在线发表
Background and purpose: Escherichia coli Nissle 1917 is a probiotic strain used in the treatment of intestinal immune diseases, including ulcerative colitis. The aim of the present study was to test if this probiotic bacterium can also show systemic immunomodulatory properties after oral administration.Experimental approach: The probiotic strain was administered to rats or mice for 2 weeks before its assay in two experimental models of altered immune response, the trinitrobenzenesulphonic acid (TNBS) model of rat colitis, localized in the colon, and the lipopolysaccharide (LPS) model of systemic septic shock in mice. Inflammatory status was evaluated both macroscopically and biochemically after 1 week in the TNBS model or after 24 h in the LPS shock model. In addition, splenocytes were obtained from mice and stimulated, ex vivo, with concanavalin A or LPS to activate T or B cells, respectively, and cytokine production (IL-2, IL-5 and IL-10) by T cells and IgG secretion by B cells measured.Key results: E. coli Nissle 1917 was anti-inflammatory in both models of altered immune response. This included a reduction in the pro-inflammatory cytokine tumour necrosis factor-alpha both in the intestine from colitic rats, and in plasma and lungs in mice treated with LPS. The systemic beneficial effect was associated with inhibited production of the T cell cytokines and by down-regulation of IgG release from splenocyte-derived B cells.Conclusions and implications: The anti-inflammatory effects of E. coli Nissle 1917 given orally were not restricted to the gastrointestinal tract. British Journal of Pharmacology (2009) 157, 1024-1033; doi:10.1111/j.1476-5381.2009.00270.x; published online 26 May 2009